The Swoosh Meets the ‘b’: Beats and Nike Unveil Historic First-Ever Collaboration for Powerbeats Pro 2
17.3.2026 15:00:00 CET | Business Wire | Press release
LeBron James trades the court for the course in a star-studded campaign celebrating the ultimate performance crossover
Today, Beats and Nike announced the first hardware collaboration in their shared history: Powerbeats Pro 2 – Nike Special Edition. In a landmark design shift, Beats has—for the first time—shared its iconic earbud real estate with a partner, featuring the Nike Swoosh on the right bud and the signature Beats “b” on the left.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317159868/en/
Powerbeats Pro 2 - Nike Special Edition
The limited-edition release marries Nike’s high-energy “Volt” color palette with the industry-leading audio tech of the Powerbeats Pro 2. The result is a performance tool built to bridge the gap between elite sport and street style.
The Nike Special Edition arrives in a striking matte black, Volt-speckled charging case. Upon opening, users are greeted by Nike’s “JUST DO IT” mantra printed inside the lid. While the aesthetic is new, the internals are pure power:
- Pro-Level Sound: Adaptive Active Noise Cancelling (ANC) and Transparency mode
- Biometric Integration: Built-in Heart Rate Monitoring that syncs seamlessly with the Fitness app and Nike Run Club1
- Athlete Endurance: Up to 45 hours of battery life with the charging case and IPX4-rated sweat and water resistance2
- Secure Fit: Signature wrap-around earhooks designed to stay put from the weight room to the 18th green
“This isn't just a new colorway; it’s a collision of two brands that define performance, culture, and sports—the attributes of today’s athlete,” said Chris Thorne, CMO of Beats. “By placing the Swoosh on our hardware for the first time, we’re honoring the shared DNA of Beats and Nike—and celebrating ambassadors like LeBron James who embody both. It’s a tribute to the grit, style, and sound that push people to their limits.”
To accompany the launch, Beats tapped longtime brand ambassador LeBron James for a comedic campaign that proves you don't need to be perfect to play. In “Keep Your Head in The Game,” James hits the green with less-than-elite golf skills—but with Powerbeats Pro 2, he tunes out the critics (played by professional golfer Tom Kim and actors Lionel Boyce and Travis "Taco" Bennett) and embraces the game on his own terms. Watch it here.
“When two iconic brands like Beats and Nike come together, it's more than a collaboration—for me, it's family,” said LeBron James. “I’ve been part of the Beats journey since day one with the original Powerbeats, and the Powerbeats Pro 2 represent everything I need in my daily routine, whether I'm training, recovering, or just living life. These aren't just my go-to earbuds—they're built for anyone who refuses to compromise on performance.”
To learn more about the collaboration and sign up for launch updates, visit Nike.Beats.
Pricing and Availability
Powerbeats Pro 2 – Nike Special Edition will be available to purchase on Friday, March 20, for $249.99 USD at Apple.com in the United States, United Kingdom, China, Japan, Germany, Canada, Australia, Singapore, France, Spain, India, Switzerland, the Netherlands, and Hong Kong. It will also be available at Nike.com in the United States and select Apple Store locations in the United States, United Kingdom, China, and Singapore.
New York
SoHo
Fifth Avenue
World Trade Center
Grand Central
Downtown Brooklyn
Williamsburg
West 14th Street
Upper West Side
Upper East Side
Los Angeles
The Grove
Beverly Center
Tower Theatre
Third Street Promenade
Century City
Manhattan Village
Chicago
Michigan Avenue
Lincoln Park
Miami
Aventura
Dadeland
Lincoln Road
Brickell City Centre
Miami Worldcenter
The Falls
London
Covent Garden
Regent Street
Brent Cross
Brompton Road
Battersea
Stratford City
White City
Shanghai
Shanghai iapm
Singapore
Marina Bay Sands
Orchard RoadJewel Changi Airport
1. Compatible hardware and software required.
2. Powerbeats Pro 2 are sweat and water resistant for non-water sports and exercise. Powerbeats Pro 2 were tested under controlled laboratory conditions, and have a rating of IPX4 under IEC standard 60529. Sweat and water resistance are not permanent conditions and resistance might decrease as a result of normal wear. Do not attempt to charge wet Powerbeats Pro 2; refer to https://support.apple.com/en-us/102013 for cleaning and drying instructions. The charging case is not sweat or water resistant.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260317159868/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom